{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:10:38Z","timestamp":1779455438088,"version":"3.53.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["175.2019.032"],"award-info":[{"award-number":["175.2019.032"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alterations in amine metabolism have been implicated in Alzheimer\u2019s disease (AD), but the relationships between plasma and cerebrospinal fluid (CSF) amine levels remain insufficiently understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate longitudinal changes in amines in plasma and CSF, as well as their cross-matrix correlations, in male and female TgF344-AD transgenic rats compared with wild-type (WT) controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>LC-MS-based targeted metabolomics was used to quantify 60 plasma amines and 55 CSF amines in male and female TgF344-AD and WT rats at 12, 25, 50 and 85 weeks of age. Generalized linear models, Pearson correlations, and Fisher\u2019s r-to-z transformation were applied for statistical analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In plasma, age- and sex-associated differences were observed. At 25 weeks, three amines (4-hydroxy-proline, homocitrulline, and hydroxylysine) showed significantly increased levels in male TgF344-AD rats after multiple-testing correction. Additional trend-level changes were observed at 12, 50, and 85 weeks. In CSF, no amines passed the significance threshold after multiple-testing correction, although descriptive age- and sex-associated patterns were observed, with earlier changes in males and later-stage trends in females. CSF\u2013plasma correlations tended to be stronger in TgF344-AD rats than in WT rats, with relatively strong correlations for alpha-aminobutyric acid, citrulline, N6,N6,N6-trimethyl-lysine, and putrescine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Body fluid, age- and sex-dependent amine alterations in CSF and plasma of TgF344-AD rats compared to WT controls provide important insights into AD disease processes and may aid early diagnosis and therapeutic targeting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-026-00811-8","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:05:20Z","timestamp":1778335520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal metabolomic profiling of biogenic amines in plasma and CSF, and their correlation, reveals sex-specific and age changes in TgF344 Alzheimer\u2019s disease transgenic and wildtype rats"],"prefix":"10.1186","volume":"23","author":[{"given":"Chunyuan","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imke","family":"Nelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Harms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Nijgh-van Kooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hankemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alida","family":"Kindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"de Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"811_CR1","doi-asserted-by":"crossref","unstructured":"2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u20133821.","DOI":"10.1002\/alz.13809"},{"issue":"5580","key":"811_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353\u20136.","journal-title":"Science"},{"issue":"4","key":"811_CR3","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr., et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"811_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"key":"811_CR5","unstructured":"Release, B.P. FDA Approval of Aduhelm. 2021; Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-grants-accelerated-approval-aduhelmtm-first-and-only#:~:text=(Tokyo%2C%20Japan)%20today%20announced,beta%20plaques%20in%20the%20brain."},{"key":"811_CR6","unstructured":"Eisai\/Biogen. FDA Approval of Leqembi. 2023; Available from: https:\/\/investors.biogen.com\/news-releases\/news-release-details\/fda-advisory-committee-votes-unanimously-confirm-clinical#:~:text=Lecanemab%20is%20a%20humanized%20immunoglobulin,)%20on%20January%206%2C%202023."},{"issue":"Suppl 2","key":"811_CR7","first-page":"S140","volume":"25","author":"B Meldrum","year":"1984","unstructured":"Meldrum B. Amino acid neurotransmitters and new approaches to anticonvulsant drug action. Epilepsia. 1984;25(Suppl 2):S140\u20139.","journal-title":"Epilepsia"},{"key":"811_CR8","unstructured":"Smith CM. Marks\u2019 basic medical biochemistry: a clinical approach. Lippincott Williams and Wilkins; 2005."},{"key":"811_CR9","unstructured":"Purves D, et al. Neurosciences: De Boeck Sup\u00e9rieur; 2019"},{"issue":"3","key":"811_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00726-019-02705-6","volume":"51","author":"E Socha","year":"2019","unstructured":"Socha E, Koba M, Ko\u015bli\u0144ski P. Amino acid profiling as a method of discovering biomarkers for diagnosis of neurodegenerative diseases. Amino Acids. 2019;51(3):367\u201371.","journal-title":"Amino Acids"},{"issue":"1","key":"811_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1021\/acs.chemrestox.1c00274","volume":"35","author":"T Syeda","year":"2022","unstructured":"Syeda T, Cannon JR. Potential Role of Heterocyclic Aromatic Amines in Neurodegeneration. Chem Res Toxicol. 2022;35(1):59\u201372.","journal-title":"Chem Res Toxicol"},{"key":"811_CR12","doi-asserted-by":"crossref","unstructured":"Griffin JW, Bradshaw PC. Amino acid catabolism in Alzheimer\u2019s disease brain: friend or foe?. Oxid Med Cell Longev. 2017;2017(1): 5472792.","DOI":"10.1155\/2017\/5472792"},{"issue":"3","key":"811_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41583-019-0132-6","volume":"20","author":"DA Butterfield","year":"2019","unstructured":"Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019;20(3):148\u201360.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"811_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1152\/physrev.00017.2006","volume":"87","author":"Y Ben-Ari","year":"2007","unstructured":"Ben-Ari Y, et al. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev. 2007;87(4):1215\u201384.","journal-title":"Physiol Rev"},{"key":"811_CR15","doi-asserted-by":"publisher","first-page":"111762","DOI":"10.1016\/j.nut.2022.111762","volume":"103\u2013104","author":"HS Yoo","year":"2022","unstructured":"Yoo HS, Shanmugalingam U, Smith PD. Potential roles of branched-chain amino acids in neurodegeneration. Nutrition. 2022;103\u2013104:111762.","journal-title":"Nutrition"},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/BF02252924","volume":"2","author":"H Basun","year":"1990","unstructured":"Basun H, et al. Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer\u2019s disease and healthy control subjects. J Neural Transmission-Parkinson\u2019s Disease Dement Sect.\u00a0 1990;2:295\u2013304.","journal-title":"J Neural Transmission-Parkinson\u2019s Disease Dement Sect"},{"issue":"1","key":"811_CR17","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41398-021-01202-3","volume":"11","author":"L Piubelli","year":"2021","unstructured":"Piubelli L, et al. Serum D-serine levels are altered in early phases of Alzheimer\u2019s disease: towards a precocious biomarker. Transl Psychiatry. 2021;11(1):77.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"811_CR18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000287953","volume":"7","author":"E Kaiser","year":"2010","unstructured":"Kaiser E, et al. Cerebrospinal fluid concentrations of functionally important amino acids and metabolic compounds in patients with mild cognitive impairment and Alzheimer\u2019s disease. Neurodegener Dis. 2010;7(4):251\u20139.","journal-title":"Neurodegener Dis"},{"key":"811_CR19","doi-asserted-by":"crossref","unstructured":"Lim NK, et al. An improved method for collection of cerebrospinal fluid from anesthetized mice. J Vis Exp. 2018;(133).","DOI":"10.3791\/56774"},{"issue":"5","key":"811_CR20","doi-asserted-by":"publisher","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina E, et al. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer\u2019s disease using metabolomics. PLoS ONE. 2013;8(5):e63644.","journal-title":"PLoS ONE"},{"issue":"2","key":"811_CR21","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s007020050057","volume":"105","author":"JA Molina","year":"1998","unstructured":"Molina JA, et al. Cerebrospinal fluid levels of non-neurotransmitter amino acids in patients with Alzheimer\u2019s disease. J Neural Transm. 1998;105(2):279\u201386.","journal-title":"J Neural Transm"},{"key":"811_CR22","doi-asserted-by":"crossref","unstructured":"Yin C, et al. Status of Metabolomic measurement for insights in Alzheimer\u2019s disease progression-what is missing?. Int J Mol Sci. 2023;24(5).","DOI":"10.3390\/ijms24054960"},{"key":"811_CR23","doi-asserted-by":"crossref","unstructured":"Karu N, et al. Severe COVID-19 Is characterised by perturbations in plasma amines correlated with immune response markers, and linked to inflammation and oxidative stress. Metabolites. 2022;12(7).","DOI":"10.3390\/metabo12070618"},{"issue":"8","key":"811_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1021\/jasms.5c00073","volume":"36","author":"M van der Peet","year":"2025","unstructured":"van der Peet M, et al. mzQuality: An Open-Source Software Tool for Quality Monitoring and Reporting of Targeted Mass Spectrometry Measurements. J Am Soc Mass Spectrom. 2025;36(8):1669\u201376.","journal-title":"J Am Soc Mass Spectrom"},{"issue":"1","key":"811_CR25","doi-asserted-by":"publisher","first-page":"17083","DOI":"10.1038\/s41598-023-41628-x","volume":"13","author":"C Lyssikatos","year":"2023","unstructured":"Lyssikatos C, et al. \u03b3-Aminobutyric acids (GABA) and serum GABA\/AABA (G\/A) ratio as potential biomarkers of physical performance and aging. Sci Rep. 2023;13(1):17083.","journal-title":"Sci Rep"},{"key":"811_CR26","unstructured":"Zhong L, et al. Key genes and pathways in asparagine metabolism in Alzheimer\u2019s disease: a bioinformatics approach. bioRxiv. 2025:2025.04. 25.650586."},{"issue":"3","key":"811_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/BF00192806","volume":"188","author":"R Brouquisse","year":"1992","unstructured":"Brouquisse R, et al. Asparagine metabolism and nitrogen distribution during protein degradation in sugar-starved maize root tips. Planta. 1992;188(3):384\u201395.","journal-title":"Planta"},{"issue":"3","key":"811_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.2174\/187152711794653742","volume":"10","author":"A Penttinen","year":"2011","unstructured":"Penttinen A, et al. Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. CNS Neurol Disorders-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disorders). 2011;10(3):340\u20138.","journal-title":"CNS Neurol Disorders-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disorders)"},{"issue":"6","key":"811_CR29","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/1073858402238515","volume":"8","author":"OA Petroff","year":"2002","unstructured":"Petroff OA. Book review: GABA and glutamate in the human brain. Neuroscientist. 2002;8(6):562\u201373.","journal-title":"Neuroscientist"},{"issue":"9","key":"811_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","volume":"24","author":"VS Sohal","year":"2019","unstructured":"Sohal VS, Rubenstein JL. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol Psychiatry. 2019;24(9):1248\u201357.","journal-title":"Mol Psychiatry"},{"issue":"2","key":"811_CR31","first-page":"67","volume":"22","author":"R Gulias-Ca\u00f1izo","year":"2021","unstructured":"Gulias-Ca\u00f1izo R, et al. The role of GABA neurotransmitter in the human central nervous system, physiology, and pathophysiology. Revista mexicana de neurociencia. 2021;22(2):67\u201376.","journal-title":"Revista mexicana de neurociencia"},{"issue":"6","key":"811_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/bies.201500004","volume":"37","author":"MA Busche","year":"2015","unstructured":"Busche MA, Konnerth A. Neuronal hyperactivity\u2013A key defect in Alzheimer\u2019s disease? BioEssays. 2015;37(6):624\u201332.","journal-title":"BioEssays"},{"issue":"4","key":"811_CR33","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3233\/JAD-230035","volume":"95","author":"I Fortel","year":"2023","unstructured":"Fortel I, et al. Disrupted excitation-inhibition balance in cognitively normal individuals at risk of Alzheimer\u2019s disease. J Alzheimer\u2019s Disease. 2023;95(4):1449\u201367.","journal-title":"J Alzheimer\u2019s Disease"},{"issue":"9","key":"811_CR34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/alz.12088","volume":"16","author":"D Bi","year":"2020","unstructured":"Bi D, et al. GABAergic dysfunction in excitatory and inhibitory (E\/I) imbalance drives the pathogenesis of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2020;16(9):1312\u201329.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"811_CR35","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1210\/er.2016-1007","volume":"37","author":"A Villa","year":"2016","unstructured":"Villa A, et al. Estrogens, Neuroinflammation, and Neurodegeneration. Endocr Rev. 2016;37(4):372\u2013402.","journal-title":"Endocr Rev"},{"issue":"1","key":"811_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox13010021","volume":"13","author":"S Chandran","year":"2023","unstructured":"Chandran S, Binninger D. Role of Oxidative Stress, Methionine Oxidation and Methionine Sulfoxide Reductases (MSR) in Alzheimer\u2019s Disease. Antioxidants. 2023;13(1):21.","journal-title":"Antioxidants"},{"issue":"49","key":"811_CR37","doi-asserted-by":"publisher","first-page":"10687","DOI":"10.1021\/bi201426b","volume":"50","author":"J Moskovitz","year":"2011","unstructured":"Moskovitz J, et al. Induction of methionine-sulfoxide reductases protects neurons from amyloid \u03b2-protein insults in vitro and in vivo. Biochemistry. 2011;50(49):10687\u201397.","journal-title":"Biochemistry"},{"key":"811_CR38","doi-asserted-by":"crossref","unstructured":"Buccellato FR, et al. Role of oxidative damage in Alzheimer\u2019s disease and neurodegeneration: from pathogenic mechanisms to biomarker discovery. Antioxid (Basel). 2021;10(9).","DOI":"10.3390\/antiox10091353"},{"issue":"1","key":"811_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JAD-2010-1222","volume":"19","author":"R Sultana","year":"2010","unstructured":"Sultana R, Butterfield DA. Role of oxidative stress in the progression of Alzheimer\u2019s disease. J Alzheimers Dis. 2010;19(1):341\u201353.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"811_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbapap.2004.09.009","volume":"1703","author":"C Sch\u00f6neich","year":"2005","unstructured":"Sch\u00f6neich C. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer\u2019s disease. Biochim et Biophys Acta (BBA)-Proteins Proteom. 2005;1703(2):111\u20139.","journal-title":"Biochim et Biophys Acta (BBA)-Proteins Proteom"},{"issue":"47","key":"811_CR41","doi-asserted-by":"publisher","first-page":"35785","DOI":"10.1074\/jbc.M602799200","volume":"281","author":"V Vitvitsky","year":"2006","unstructured":"Vitvitsky V, et al. A Functional Transsulfuration Pathway in the Brain Links to Glutathione Homeostasis *. J Biol Chem. 2006;281(47):35785\u201393.","journal-title":"J Biol Chem"},{"issue":"13","key":"811_CR42","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.3390\/ijms26136430","volume":"26","author":"L Flori","year":"2025","unstructured":"Flori L, et al. Transsulfuration Pathway Products and H2S-Donors in Hyperhomocysteinemia: Potential Strategies Beyond Folic Acid. Int J Mol Sci. 2025;26(13):6430.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"811_CR43","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.freeradbiomed.2010.11.026","volume":"51","author":"M Dumont","year":"2011","unstructured":"Dumont M, Beal MF. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic Biol Med. 2011;51(5):1014\u201326.","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"811_CR44","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41398-023-02437-y","volume":"13","author":"E Granot-Hershkovitz","year":"2023","unstructured":"Granot-Hershkovitz E, et al. Genetic loci of beta-aminoisobutyric acid are associated with aging-related mild cognitive impairment. Translational Psychiatry. 2023;13(1):140.","journal-title":"Translational Psychiatry"},{"issue":"1","key":"811_CR45","doi-asserted-by":"publisher","first-page":"e1003012","DOI":"10.1371\/journal.pmed.1003012","volume":"17","author":"UV Mahajan","year":"2020","unstructured":"Mahajan UV, et al. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study. PLoS Med. 2020;17(1):e1003012.","journal-title":"PLoS Med"},{"issue":"1","key":"811_CR46","doi-asserted-by":"publisher","first-page":"15205","DOI":"10.1038\/s41598-022-19670-y","volume":"12","author":"T Ozaki","year":"2022","unstructured":"Ozaki T, et al. Metabolomic alterations in the blood plasma of older adults with mild cognitive impairment and Alzheimer\u2019s disease (from the Nakayama Study). Sci Rep. 2022;12(1):15205.","journal-title":"Sci Rep"},{"issue":"7","key":"811_CR47","doi-asserted-by":"publisher","first-page":"10770","DOI":"10.18632\/aging.202928","volume":"13","author":"B Polis","year":"2021","unstructured":"Polis B, Karasik D, Samson AO. Alzheimer\u2019s disease as a chronic maladaptive polyamine stress response. Aging. 2021;13(7):10770.","journal-title":"Aging"},{"issue":"7","key":"811_CR48","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1128\/AAC.02649-14","volume":"58","author":"OM El-Halfawy","year":"2014","unstructured":"El-Halfawy OM, Valvano MA. Putrescine reduces antibiotic-induced oxidative stress as a mechanism of modulation of antibiotic resistance in Burkholderia cenocepacia. Antimicrob Agents Chemother. 2014;58(7):4162\u201371.","journal-title":"Antimicrob Agents Chemother"},{"key":"811_CR49","doi-asserted-by":"crossref","unstructured":"Arthur R, Jamwal S, Kumar P. A review on polyamines as promising next-generation neuroprotective and anti-aging therapy. Eur J Pharmacol. 2024;978:176804.","DOI":"10.1016\/j.ejphar.2024.176804"},{"issue":"3","key":"811_CR50","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1134\/S1819712422030059","volume":"16","author":"M Makletsova","year":"2022","unstructured":"Makletsova M, et al. The role of polyamines in the mechanisms of cognitive impairment. Neurochemical J. 2022;16(3):283\u201394.","journal-title":"Neurochemical J"},{"issue":"4","key":"811_CR51","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"key":"811_CR52","doi-asserted-by":"crossref","unstructured":"Zhang F, Jiang L. Neuroinflammation in Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2015: 243\u2013256.","DOI":"10.2147\/NDT.S75546"},{"issue":"6","key":"811_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.jalz.2016.02.010","volume":"12","author":"V Calsolaro","year":"2016","unstructured":"Calsolaro V, Edison P. Neuroinflammation in Alzheimer\u2019s disease: current evidence and future directions. Alzheimer\u2019s Dement. 2016;12(6):719\u201332.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"5","key":"811_CR54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-024-01104-7","volume":"25","author":"MT Heneka","year":"2025","unstructured":"Heneka MT, et al. Neuroinflammation in Alzheimer disease. Nat Rev Immunol. 2025;25(5):321\u201352.","journal-title":"Nat Rev Immunol"},{"key":"811_CR55","doi-asserted-by":"crossref","unstructured":"Smith MA, et al. Oxidative stress in Alzheimer\u2019s disease. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2000;1502(1):139\u201344.","DOI":"10.1016\/S0925-4439(00)00040-5"},{"issue":"5","key":"811_CR56","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/br.2016.630","volume":"4","author":"W-J Huang","year":"2016","unstructured":"Huang W-J, Zhang X, Chen W-W. Role of oxidative stress in Alzheimer\u2019s disease. Biomedical Rep. 2016;4(5):519\u201322.","journal-title":"Biomedical Rep"},{"issue":"4","key":"811_CR57","doi-asserted-by":"publisher","first-page":"S1016","DOI":"10.1093\/jn\/130.4.1016S","volume":"130","author":"QR Smith","year":"2000","unstructured":"Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000;130(4):S1016\u201322.","journal-title":"J Nutr"},{"issue":"1","key":"811_CR58","first-page":"9484217","volume":"2022","author":"Y Liang","year":"2022","unstructured":"Liang Y, et al. Kynurenine pathway metabolites as biomarkers in Alzheimer\u2019s disease. Dis Markers. 2022;2022(1):9484217.","journal-title":"Dis Markers"},{"issue":"6","key":"811_CR59","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s11064-022-03546-8","volume":"47","author":"VK Sharma","year":"2022","unstructured":"Sharma VK, et al. Kynurenine metabolism and Alzheimer\u2019s disease: the potential targets and approaches. Neurochem Res. 2022;47(6):1459\u201376.","journal-title":"Neurochem Res"},{"issue":"1","key":"811_CR60","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s10571-024-01496-z","volume":"44","author":"R Kearns","year":"2024","unstructured":"Kearns R. Gut\u2013brain axis and neuroinflammation: The role of gut permeability and the kynurenine pathway in neurological disorders. Cell Mol Neurobiol. 2024;44(1):64.","journal-title":"Cell Mol Neurobiol"},{"issue":"6","key":"811_CR61","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","volume":"56","author":"S Fukui","year":"1991","unstructured":"Fukui S, et al. Blood\u2013brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56(6):2007\u201317.","journal-title":"J Neurochem"},{"issue":"10","key":"811_CR62","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s11010-023-04872-3","volume":"479","author":"F Huf","year":"2024","unstructured":"Huf F, et al. Neuroprotection elicited by taurine in sporadic Alzheimer-like disease: benefits on memory and control of neuroinflammation in the hippocampus of rats. Mol Cell Biochem. 2024;479(10):2663\u201378.","journal-title":"Mol Cell Biochem"},{"issue":"6","key":"811_CR63","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.3390\/nu14061292","volume":"14","author":"Z Rafiee","year":"2022","unstructured":"Rafiee Z, Garc\u00eda-Serrano AM, Duarte JM. Taurine supplementation as a neuroprotective strategy upon brain dysfunction in metabolic syndrome and diabetes. Nutrients. 2022;14(6):1292.","journal-title":"Nutrients"},{"issue":"5","key":"811_CR64","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1046\/j.1471-4159.2002.01223.x","volume":"83","author":"YS Kang","year":"2002","unstructured":"Kang YS, et al. Regulation of taurine transport at the blood\u2013brain barrier by tumor necrosis factor-\u03b1, taurine and hypertonicity. J Neurochem. 2002;83(5):1188\u201395.","journal-title":"J Neurochem"},{"issue":"5","key":"811_CR65","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth analgesia. 2018;126(5):1763\u20138.","journal-title":"Anesth analgesia"},{"issue":"1","key":"811_CR66","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5483\/BMBRep.2020.53.1.309","volume":"53","author":"J-C Park","year":"2020","unstructured":"Park J-C, Han S-H, Mook-Jung I. Peripheral inflammatory biomarkers in Alzheimer\u2019s disease: a brief review. BMB Rep. 2020;53(1):10.","journal-title":"BMB Rep"},{"issue":"10","key":"811_CR67","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1136\/jnnp-2017-316201","volume":"88","author":"KSP Lai","year":"2017","unstructured":"Lai KSP, et al. Peripheral inflammatory markers in Alzheimer\u2019s disease: a systematic review and meta-analysis of 175 studies. J Neurol Neurosurg Psychiatry. 2017;88(10):876\u201382.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"811_CR68","doi-asserted-by":"publisher","first-page":"530219","DOI":"10.3389\/fnins.2020.530219","volume":"14","author":"X Yan","year":"2020","unstructured":"Yan X, et al. Metabolic dysregulation contributes to the progression of Alzheimer\u2019s disease. Front NeuroSci. 2020;14:530219.","journal-title":"Front NeuroSci"},{"issue":"1","key":"811_CR69","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12974-024-03218-0","volume":"21","author":"C Otto","year":"2024","unstructured":"Otto C, et al. Comprehensive analysis of the cerebrospinal fluid and serum metabolome in neurological diseases. J Neuroinflamm. 2024;21(1):234.","journal-title":"J Neuroinflamm"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-026-00811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T13:02:33Z","timestamp":1779454953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12987-026-00811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1186\/s12987-026-00811-8","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal protocols were approved by the Leiden University Animal Welfare Body (AWB: AVD1060020171766). All animal experiments were conducted in accordance with the ARRIVE guidelines (ARRIVE 2.0).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}